hrp0097rfc8.1 | Fat, metabolism and obesity 2 | ESPE2023

A novel heterozygous likely pathogenic variant in GNB1 causing hyperphagia, severe early onset obesity and neurodevelopmental disorder

Karantza Maria , Hun Seo Go , Hyun Seong-In , Lee Hane , Kitsiou Sophia , Michala Lina , Kostopoulou Eirini

The proband is a 12 yr old Caucasian European girl with grade 3 obesity, developmental delay and hyperphagia. She was born at term via an uncomplicated pregnancy and exhibited neonatal hypotonia, difficulty feeding, failure to thrive and delayed attenuation of milestones. At the age of 2 years she started developing hyperphagia and rapid excessive weight gain. Molecular analysis for Prader Willi syndrome and array CGH were negative. At the age of 10 yrs she was diagnosed with ...

hrp0097p2-58 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Kenny Caffey syndrome 2; expanding the clinical spectrum

Hatziagapiou Kyriaki , Sertedaki Amalia , Dermentzoglou Vasiliki , Kanaka-Gantenbein Christina , D. Sakka Sophia

Background: Kenny–Caffey syndrome 2 (KCS 2) is a rare cause of hypoparathyroidism, characterized by proportionate short stature, cortical thickening and medullary stenosis of tubular long bones, delayed closure of anterior fontanel and eye abnormalities.Objective: We report the case of a 4-years’-old boy, who presented with the characteristic, and newly identified clinical, biochemical, radiological and genet...

hrp0084p3-982 | GH & IGF | ESPE2015

Experience of the Use of Genetically Engineered GH ‘Rastan’ by Children in Clinical Practice

Kulagina Elena , Savelyeva Elena , Chistousova Galina

Objective: To evaluate the efficacy of the drug ‘Rastan’, (manufacturer JSC ‘Pharmstandard-Ufa Vita’), in children with GH deficiency at the beginning of treatment at different ages.Materials and methods: We examined two groups of patients with GH deficiency who receive the drug for 3 years. In group 1, nine boys and two girls with age at debut of therapy 5.88±1.35 (from 3.3 to 7.1 years); in the 2nd group of ten boys and two gir...

hrp0092p3-166 | Growth and Syndromes (to include Turner Syndrome) | ESPE2019

Growth Hormone Treatment and Puberty in Patient with Pallister-Hall Syndrome

Pisareva Elena , Vitebskaya Alisa

Background: Pallister-Hall syndrome (PHS) is a rare autosomal dominant disorder characterized by a complex of different abnormalities (polydactyly, bifid epiglottis, hypothalamic hamartoma, imperforate anus). Syndrome is cuased by mutations in the GLI3 gene. PHS is associated with hypopituitarism, early or precocious puberty.Objective: to demonstrate a patient with PHS treated with growth hormone (GH) and gonadotropin re...

hrp0086p1-p561 | Perinatal Endocrinology P1 | ESPE2016

A Case of Hyperinsulinemic Hypoglycemia, Associated with Insulin Autoimmune Syndrome (IAS) in 3.5 Year Old Girl

Kuznetsova Elena , Melikyan Mariya

Background: Insulin Autoimmune Syndrome (IAS) is a rare cause of hyperinsulinemic hypoglycaemia with only few descriptions in children in the literature. Drugs containing the sulfhydryl group, such as methimazol, are known to be a causative factor of this syndrome. Diazoxide and octreotide are usually ineffective in such patients.Objective: We aim to describe a rare case of IAS in a child, with a good response to a short course of glucocorticoid therapy....

hrp0097p1-243 | Diabetes and Insulin | ESPE2023

A comparison of Quality of Life in Children with Diabetes Type 1 in Cyprus treated with Multiple daily injections of insulin to children utilizing CGM as adjutant to MDI and to children treated with Continuous Subcutaneous Insulin Infusion.

Sotiriou Elena , Skordis Nicos

Background: Insulin remains the mainstay treatment for diabetes type 1(T1D), more recently several technological advances have been introduced to assist with the treatment. Continuous Subcutaneous insulin infusion (CSII) devices and continues glycose monitors (CGM) have gained a lot of popularity and are thought to help patients achieve better glycaemic control. HbA1c levels can be used to assess glycaemic control. There are conflicting reports on whether thos...

hrp0092p3-270 | Late Breaking Abstracts | ESPE2019

A Real World, Clinical Experience of Burosumab Therapy in a Cohort of Children with X-Linked Hypophosphataemia

Sandy Jessica , Gilbey-Cross Robyn , Santos Rui , Cocca Alessandra , Sakka Sophia , Morris Mavali , Massey Jill , Cheung Moira

Burosumab, a monoclonal antibody targeting fibroblast growth factor 23, is now available for clinical use in children with X-linked hypophosphatemia (XLH). We explored the effects of this treatment in a clinical setting, considering biochemistry, growth, deformity, functionality, quality of life, pain and fatigue.Methods: Clinical, biochemical, radiological and questionnaire data were reviewed at 6 and 12 months in a cohort of 8 children...

hrp0089p1-p029 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Fracture Epidemiology for Children in Western Australia between 2005–2015: Do We Need to be Concerned about Bone Health?

Jenkins Mark , Nimphius Sophia , Hart Nicolas , Chivers Paola , Rantalainen Timo , Ruter Kristina , Borland Meredith , McIntyre Fleur , Stannage Katherine , Siafarikas Aris

Aim: Western Australia is a state with unique geography and population distribution having only a single tertiary paediatric hospital (Princess Margaret Hospital, PMH in Perth) managing the majority of children and adolescents with fractures in the Emergency Department (ED). Fracture incidence in 0–16 year olds is known to be high and varies between countries with boys having a 1.5 fold higher fracture incidence than girls. There are no specific data for Australia. The ai...

hrp0086p1-p16 | Adrenal P1 | ESPE2016

Cortisol Response to ACTH Stimulation Test in Non-Classical Congenital Adrenal Hyperplasia

Karachaliou Feneli , Kafetzi Maria , Vlachopapadopoulou Elpis , Leka-Emiris Sophia , Drakopoulou Maria , Kapella Antonia , Fotinou Aspasia , Michalakos Stefanos

Background: The adequacy of cortisol response in NCCAH has not been fully elucidated.Objective and hypotheses: To evaluate cortisol response to ACTH stimulation test in children and adolescents with NCCAH and possible heterozygosity for CYP21 gene molecular defects.Method: Data of ACTH stimulation test from 146 children and adolescents with clinical hyperandogenism were evaluated retrospectively. Cortisol responses to ACTH stimulat...

hrp0084p2-168 | Adrenals | ESPE2015

The Natural Mutant Receptor hGRαT556I Causes Primary Generalised Glucocorticoid Resistance Through Decreased Affinity for the Ligand and Impaired Interaction with the GRIP1 Coactivator

Nicolaides Nicolas C , Skyrla Eirini , Vlachakis Dimitrios , Psarra Anna-Maria G , Sertedaki Amalia , Kossida Sophia , Charmandari Evangelia

Background: Primary generalised glucocorticoid resistance (PGGR) is a rare condition characterised by tissue insensitivity to glucocorticoids owing to inactivating mutations of the hGR gene. A new case of PGGR was reported in a patient with an adrenal incidentaloma harboring a novel heterozygous point mutation in the hGR gene, which resulted in threonine (T) to isoleucine (I) substitution at amino acid position 556 of the receptor.Objec...